Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Biohit Oyj's Enterprise Value is €36.73 Mil.
Biohit Oyj's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €3.10 Mil. Therefore, Biohit Oyj's EV-to-EBIT ratio for today is 11.85.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Biohit Oyj's Enterprise Value is €36.73 Mil.
Biohit Oyj's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €3.70 Mil. Therefore, Biohit Oyj's EV-to-EBITDA ratio for today is 9.93.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Biohit Oyj's Enterprise Value is €36.73 Mil.
Biohit Oyj's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was €15.70 Mil. Therefore, Biohit Oyj's EV-to-Revenue ratio for today is 2.34.
EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, Biohit Oyj's Enterprise Value is €36.73 Mil.
Biohit Oyj's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €-1.70 Mil. Therefore, Biohit Oyj's EV-to-FCF ratio for today is -21.61.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Biohit Oyj (LTS:0DRP) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Biohit Oyj's current Enterprise Value is €36.73 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Biohit Oyj's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €3.10 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Biohit Oyj's current Enterprise Value is €36.73 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Biohit Oyj's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €3.70 Mil.
Biohit Oyj's current Enterprise Value is €36.73 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Biohit Oyj's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was €15.70 Mil.
Biohit Oyj's current Enterprise Value is €36.73 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Biohit Oyj's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was €-1.10 Mil.
Biohit Oyj's current Enterprise Value is €36.73 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Biohit Oyj's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €-1.70 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biohit Oyj Enterprise Value Related Terms
Biohit Oyj Enterprise Value Historical Data
* Premium members only.
The historical data trend for Biohit Oyj's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0DRP vs ABT, SYK, MDT: Enterprise Value Comparison
For the Medical Devices subindustry, Biohit Oyj's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biohit Oyj Enterprise Value vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Biohit Oyj's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Biohit Oyj's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Biohit Oyj's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biohit Oyj (LTS:0DRP) has a Enterprise Value of €36.73 Mil as of Jun. 30, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Biohit Oyj and its competitors.
Is Biohit Oyj's Enterprise Value too high?
Biohit Oyj's current Enterprise Value is €36.73 Mil. Overall, Biohit Oyj has a GF Score™ of 79/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Biohit Oyj's Enterprise Value compare to ABT and SYK?
Biohit Oyj's Enterprise Value of €36.73 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Medical Devices & Instruments company?
A good Enterprise Value depends on the Medical Devices & Instruments industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Biohit Oyj and its competitors. Biohit Oyj's current Enterprise Value is €36.73 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biohit Oyj stock overvalued right now?
Based on GuruFocus' analysis, Biohit Oyj (LTS:0DRP) is currently considered Fairly Valued. The stock's GF Value™ is €2.76, compared to a current price of €2.62 — trading 5.1% below its estimated fair value. The current Enterprise Value is €36.73 Mil. Biohit Oyj's overall GF Score™ is 79/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Biohit Oyj (LTS:0DRP), the current Enterprise Value is €36.73 Mil as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biohit Oyj (LTS:0DRP) Overvalued in 2026?
Based on GuruFocus' analysis, Biohit Oyj stock appears to be undervalued.
The current stock price of €2.62 is trading 5.1% below its estimated GF Value™ of €2.76.
GuruFocus considers Biohit Oyj to be Fairly Valued.
Key valuation signals for LTS:0DRP:
Enterprise Value: €36.73 Mil
GF Value™: €2.76 vs. price of €2.62 (5.1% below fair value)
No single metric tells the full story. See the LTS:0DRP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biohit Oyj is a globally operating Finnish biotechnology company that develops diagnostic and other health products. Its products include GastroPanel quick test assesses the structure and function of the stomach lining; ColonView quick test is an immunochemical fecal occult blood test (FIT) developed; Acetium capsules protect the stomach lining from carcinogenic acetaldehyde, especially in people with acid-free stomachs. The company's product portfolio consists of diagnostic tests, analysis systems, products binding carcinogenic acetaldehyde into a harmless compound and monoclonal antibodies.
79GF Score
Get the complete analysis for LTS:0DRP
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0DRP has been successfully added to your 
